Research PaperJournal of Pharmacology and PharmacotherapeuticsVol. 12 | Issue 1 | 2021 | pp. 10–13Open access
Comparison of Intravenous Ramosetron and Ondansetron as Prophylaxis for Postoperative Nausea and Vomiting following General Anesthesia
- 1,
- 2,
- 2*,
- 2
- 1 Department of Anaesthesia, Sardar Patel Medical College, Bikaner, Rajasthan, India.
- 2 Department of Anaesthesiology, Goa Medical College, Bambolim, Goa, India.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Roopesh Sureshan
Department of Anaesthesiology, Goa Medical College, Bambolim, Goa, India.
Email: roopesh14488@gmail.com
Copyright: © 2021 Manuscript Technomedia LLP. This is an open access article.
- Published:
- Jan 1, 2021
- Received:
- Dec 16, 2020
- Accepted:
- Mar 17, 2021
How to cite
Opneja, S., Souza, S. A. D., Sureshan, R., & Ghoshal, P. (2021). Comparison of Intravenous Ramosetron and Ondansetron as Prophylaxis for Postoperative Nausea and Vomiting following General Anesthesia. Journal of Pharmacology and Pharmacotherapeutics, 12(1), 10–13. https://doi.org/10.4103/jpp.JPP_163_20
Abstract
Objective: To compare the efficacy and side effects of 5HT3 antagonists, ramosetron, and ondansetron as prophylaxis for postoperative nausea and vomiting (PONV) following general anesthesia.
Materials and Methods: One hundred and ten patients of the American Society of Anesthesiology Grade I–II, between the age group of 18 to 60 years weighing 40 to 70 kg, undergoing general anesthesia were studied. Group 1 received ramosetron 0.3 mg intravenous (IV) and Group 2 received ondansetron 8 mg IV 15 min before the end of surgery. The incidence of PONV, need for rescue antiemetic, and side effects were evaluated in both the groups. QTc interval prolongation was also evaluated in both the groups by taking electrocardiograms at regular intervals.
Results: This study showed that there was no statistically significant difference in the incidence of PONV between the ondansetron group and the ramosetron group during the first 24 h after surgery. For PONV score of ≥2 during the first 6 h, the incidence was 3.59% and 1.81% for ramosetron and ondansetron, respectively, and during 6–24 h, the incidence was 1.81% for both the drugs.
Conclusion: IV ramosetron 0.3 mg is as effective as IV ondansetron 8 mg in preventing PONV in patients undergoing general anesthesia.
Keywords
Subject
Article metadata
| Title | Comparison of Intravenous Ramosetron and Ondansetron as Prophylaxis for Postoperative Nausea and Vomiting following General Anesthesia |
|---|---|
| Authors | Sonali Opneja; Shirley Ann D Souza; Roopesh Sureshan; Pabitra Ghoshal |
| Affiliations | Department of Anaesthesia, Sardar Patel Medical College, Bikaner, Rajasthan, India.; Department of Anaesthesiology, Goa Medical College, Bambolim, Goa, India. |
| Corresponding author | roopesh14488@gmail.com |
| Journal | Journal of Pharmacology and Pharmacotherapeutics |
| Volume / Issue | Vol. 12, Issue 1 (2021) |
Also in this issue
- Efficacy and Safety Comparison between Pioglitazone and Linagliptin in Combination with Metformin among Patients with Type 2 Diabetes Mellitus: A Meta‑Analysis of Randomized Controlled Trialspp. 1–9
- Effect of HMG-Co-A Reductase Inhibitors on Cardiac Autonomic Neuropathy in Diabetic Patientspp. 14–19
- Antibacterial Use in Admitted Patients of a Super Speciality Hospital in Western Indiapp. 20–22
- Protamine-Induced Hypotension and Pulmonary Arterial Hypertensionpp. 23–25
- Relugolix: A Novel Gonadotropin‑Releasing Hormone Antagonist for Prostate Cancerpp. 26–28
Readers Also Viewed
Effect of the Fractions of Coccinia grandis on Ethanol- Induced Cerebral Oxidative Stress in Rats
M. Umamaheswari, T. K. Chatterjee
Jan 1, 2009
Phytochemical Screening and Antioxidant Activity Evaluation of Selected Philippine Fruit Peels and Pulps
Mildred Dagcuta Pates, Angelo Mark Po Walag, Romeo M. Del Rosario
Aug 17, 2026
Impact of Artificial Intelligence Assisted Drug Therapy Optimization on Drug Related Problems Amongst Older Adult Patients: A Systematic Review
Jehath Syed, Christy Thomas, Bavneet Kaur
Oct 23, 2026